AccuMetab™ Canine CYP3A26 Enzyme, Catalytically Active

CAT#: ITS-0426-YL39
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Canine CYP3A26 for reliable preclinical Phase I ADME profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
Operating alongside CYP3A12, CYP3A26 contributes significantly to the total CYP3A-mediated clearance capacity in dog models. Resolving its specific metabolic contributions ensures high-fidelity scaling of multi-pathway drug candidates prior to first-in-human clinical trials.
Key Features
Complementary canine CYP3A clearance pathway; Enhances allometric scaling accuracy; Evaluates multi-pathway preclinical candidates; Supplied in controlled, low-reductase formats
Applications
Drug Metabolism Studies, Preclinical Species Comparison
Research Areas
ADME; Veterinary Pharmacology
Species
Beagle
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
1 nmol
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry